Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
| Status: | Recruiting |
|---|---|
| Conditions: | Liver Cancer, Cancer, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/28/2018 |
| Start Date: | January 2, 2018 |
| End Date: | January 2020 |
| Contact: | Shamar J Young, MD |
| Email: | youn1862@umn.edu |
| Phone: | 612-626-5388 |
Safety of Transarterial Chemoembolization in Patients With Elevated Bilirubin
The aim of this study is to evaluate the safety of selective transarterial chemoembolization
(TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but
relatively normal direct bilirubin.
(TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but
relatively normal direct bilirubin.
Inclusion Criteria:
- hepatocellular carcinoma (HCC)
- Direct or conjugated bilirubin < 3 mg/dl
- Total bilirubin > 3 mg/dl
- Willing and able to provide informed consent
- >18 years of age
Exclusion Criteria:
- Currently pregnant
- Patients who are surgical or ablation candidates as determined by multidisciplinary
hepatobiliary tumor conference.
- Arterial anatomy which would preclude selective transarterial chemoembolization
- Patients who have a INR or platelet count which are not correctable to <1.8 and
>35,000 respectively
- Patients with extrahepatic metastases
- Patients with portal vein invasion
We found this trial at
1
site
Minneapolis, Minnesota 55455
(612) 625-5000
Principal Investigator: Shamar Young, MD
Phone: 612-624-6904
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
Click here to add this to my saved trials
